NASDAQ:IBRX ImmunityBio 5/9/2024 Earnings Report $2.37 -0.01 (-0.42%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.38 +0.01 (+0.63%) As of 09/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ImmunityBio EPS ResultsActual EPS-$0.20Consensus EPS -$0.16Beat/MissMissed by -$0.04One Year Ago EPSN/AImmunityBio Revenue ResultsActual Revenue$0.04 millionExpected Revenue$0.03 millionBeat/MissBeat by +$10.00 thousandYoY Revenue GrowthN/AImmunityBio Announcement DetailsQuarterDate5/9/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsImmunityBio's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile ImmunityBio Earnings HeadlinesImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent GlioblastomaAugust 31, 2025 | msn.comImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ PlatformAugust 28, 2025 | insidermonkey.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)What ImmunityBio (IBRX)'s Early Glioblastoma Disease Control Results Could Mean for ShareholdersAugust 27, 2025 | finance.yahoo.comInitial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® DeviceAugust 26, 2025 | mms.businesswire.comImmunityBio announces Anktiva trialAugust 20, 2025 | msn.comSee More ImmunityBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email. Email Address About ImmunityBioImmunityBio (NASDAQ:IBRX) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications. Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity. Anktiva is being evaluated in combination with tumor-targeting monoclonal antibodies and immune checkpoint inhibitors for treatment of non–muscle-invasive bladder cancer as well as other solid tumors. In parallel, ImmunityBio is advancing novel T cell receptor (TCR) therapies and off-the-shelf NK cell products aimed at solid and hematologic malignancies. Beyond oncology, the company has pursued viral-vectored vaccine candidates for infectious diseases, including a Phase 1 program for COVID-19. These efforts leverage a proprietary human adenovirus (hAd5) backbone intended to elicit robust cellular and humoral immune responses. ImmunityBio’s integrated approach combines cell engineering, cytokine biology and vaccine technology to build a diversified pipeline across multiple therapeutic areas. Founded as NantKwest and rebranded to ImmunityBio in 2020, the company operates under the leadership of CEO Tarek Tantawi and was co-founded by biotech entrepreneur Dr. Patrick Soon-Shiong. Headquartered in Culver City, California, ImmunityBio conducts preclinical research and clinical trials in North America, Europe and Australia. The company maintains collaborations with academic institutions, government agencies and industry partners to accelerate development and regulatory filings for its immunotherapy candidates.Written by Jeffrey Neal JohnsonView ImmunityBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles What to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Upcoming Earnings Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
